口腔医学研究

口腔医学研究 ›› 2016, Vol. 32 ›› Issue (7): 712-715.DOI: 10.13701/j.cnki.kqyxyj.2016.07.012

• 临床研究论著 • 上一篇    下一篇

涎腺导管癌10例临床分析

克热木·阿巴司, 陈青立, 凌彬, 刘慧, 林兆全, 龚忠诚*   

  1. 新疆医科大学第一附属医院颌面肿瘤外科 新疆 乌鲁木齐 830054
  • 收稿日期:2015-12-01 出版日期:2016-07-26 发布日期:2016-07-25
  • 通讯作者: 龚忠诚,E-mail:gump0904@aliyun.com
  • 作者简介:克热木·阿巴司,男,主治医师,主要从事口腔颌面部创伤及脉管性疾病的研究。
  • 基金资助:
    2012年国家自然科学基金(地区科学基金)资助项目(项目号:31260229)

Salivary Duct Carcinoma: A Clinical Analysis of 10 Cases.

KEREMU Abasi, CHEN Qing-li, LING Bin, LIU Hui, LIN Zhao-quan, GONG Zhong-cheng*.   

  1. Oncological Department of Oral and Mxillofacial Surgery, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China
  • Received:2015-12-01 Online:2016-07-26 Published:2016-07-25

PDF (PC)

462

摘要： 目的: 分析涎腺导管癌的临床特点以及治疗效果。方法: 回顾分析2007年10月~2014年11月经术后病理确诊且完成随访患者的临床资料。结果: 10例患者中,男性8例,女性2例,年龄46~89岁,平均(64.7±12.7)岁。8例累及腮腺,2例累及颌下腺。临床表现为腮腺区或颌下区肿物,可伴有近期突然增大,局部神经侵犯症状。影像学发现局部占位性病变,边界多为不清,不均匀强化。10例患者均行手术治疗,术后6例予以放疗,4例未放疗。随访至术后7~97个月,中位无病生存时间为37.5个月。10人均随访满1年,其中1例复发,1年无病生存率为90%(95%CI:55-100),8人随访满3年,其中3人复发,3年无病生存率为62.5%(95%CI:24-91),7人随访满5年,其中3人复发,5年无病生存率为57.1%(95%CI:18-90)。结论: 涎腺导管癌较罕见,临床表现及辅助检查无明显特异性,确诊主要依靠病理结果。该疾病预后较差,手术治疗为首选方法,术后需联合放疗。生物靶向治疗有望成为新的辅助治疗方式之一。

关键词: 导管癌, 涎腺肿瘤, 临床分析

Abstract: Objective: To evaluate the clinical manifestation, treatment and prognosis of patients with salivary duct carcinoma (SDC). Methods: Clinical data of 10 patients with SDC from Oct. 2007 to Nov. 2014 were collected and retrospectively analyzed. Results: In this study, the included patients with SDC (8 male and 2 female) were aged from 49 years to 89 years with mean age 64.7 years. With 8 cases of parotid gland and 2 cases of submandibular gland, the patients presented regional mass characterized by recent rapid growth and neural impairment. CT images revealed the mass with ill-defined margin and inhomogeneous enhancement. For the treatment, only six patients received post-operative radiotherapy. Follow-up period was 7 months to 97 months. Three patients recurred. The median survival time was 37.5 months. The 1-, 3-, 5-year disease-free survival rates of these 10 patients with SDC were 90% (95% CI: 55-100), 62.5% (95% CI: 24-91) and 57.1% (95% CI: 18-90), respectively. Conclusion: SDC was a rare disease. The clinical manifestation and imaging examination were not outstanding, while pathological report could guide diagnosis. With poor prognosis, surgery was the first choice and post-operative radiotherapy should be performed. Biological therapy might be a novel treatment strategy for SDC.

Key words: Duct carcinoma , Salivary gland neoplasms , Clinical analysis

中图分类号: